NCT06987643

A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: EIP Pharma Inc · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.

Conditions

• Moderate to Severe Acute Ischaemic Stroke
• Ischaemic Stroke

Interventions

Type	Name	Description
DRUG	Neflamapimod	Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
DRUG	Placebo	Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Timeline

• Start date: 2025-06-20
• Primary completion: 2026-05-31
• Completion: 2026-06-28
• First posted: 2025-05-23
• Last updated: 2026-02-09

Locations

12 sites across 1 country: Australia

Regulatory

• FDA-regulated drug study